Lianaevans (Talk | contribs) m |
Lianaevans (Talk | contribs) m |
||
Line 38: | Line 38: | ||
</div> | </div> | ||
</section> | </section> | ||
− | + | <section class="project-description-content"> | |
+ | <div class="container"> | ||
+ | <div class="row"> | ||
+ | <div class="col-lg-6 venn-diagram"> | ||
+ | <img src="https://static.igem.org/mediawiki/2020/7/79/T--Queens_Canada--venn-diagram.png" alt=""> | ||
+ | </div> | ||
+ | <div class="col-lg-6 phosphate-intro"> | ||
+ | <h5>Phosphate levels are associated with a slew of cardiovascular and renal complications, with | ||
+ | hyperphosphatemia serving as a direct stimulus to vascular calcification in CKD patients. As phosphate | ||
+ | begins to build up, our mineral homeostasis goes off course – resulting in capillaries being clogged | ||
+ | and our bones breaking down. Currently, there is no point-of-care method for phosphate detection, with | ||
+ | blood analysis being the main clinical diagnostic tool. Other biomarker abnormalities like elevated | ||
+ | potassium, FGF23, and PTH are also associated with CKD. A weak kidney may lead to other problems like | ||
+ | vascular calcification and bone abnormalities – resulting in serious illness and eventually death. | ||
+ | After speaking with nephrologists, many CKD patients are diabetic, so glucose is also a valuable | ||
+ | biomarker to detect for patient car</h5> | ||
+ | </div> | ||
+ | |||
+ | </div> | ||
+ | </div> | ||
+ | </section> | ||
<!--Inserting the particles script again here--> | <!--Inserting the particles script again here--> |
Revision as of 17:33, 4 August 2020